Greenwich LifeSciences delays FY2025 10-K, FLAMINGO-01 arm shows 70-80% recurrence drop
Greenwich LifeSciences expects its audited FY2025 Form 10-K and Q1 10-Q by end-May after auditors address accounts payable from accelerated global Phase III trial spending and higher European patient screening. Unaudited cash totaled $10.5 million at March 31, while FLAMINGO-01’s non-HLA-A*02 arm (250 patients) shows a preliminary 70-80% recurrence reduction.
1. Form 10-K and 10-Q Filing Update
Greenwich LifeSciences reports its Form 10-K for the fiscal year ending December 31, 2025 remains under audit, with auditors reconciling accounts payable linked to expanded global Phase III trial expenses. The company expects to complete audits and file both the 10-K and the Q1 10-Q by the end of May.
2. Cash Balance and Accounts Payable
As of March 31, 2026, the company's unaudited cash balance stood at approximately $10.5 million, subject to change upon audit completion. Increased accounts payable reflect unexpected spikes in European patient screening and enrollment during 2024–2025 tied to the FLAMINGO-01 trial.
3. FLAMINGO-01 Phase III Enrollment and Results
The Phase III FLAMINGO-01 trial has screened over 1,300 patients at a rate of roughly 800 per year, with 250 non-HLA-A*02 patients fully enrolled. Preliminary analysis indicates a 70–80% reduction in breast cancer recurrence after the primary immunization series, consistent with prior Phase IIb outcomes.